Risk of Hyponatremia in Patients with Aneurysmal Subarachnoid Hemorrhage Treated with Exogenous Vasopressin Infusion.
Vasopressin is one of the vasopressors used to augment blood pressure in subarachnoid hemorrhage (SAH) patients with clinically significant vasospasm. The purpose of the present study was to determine whether the administration of vasopressin to a population of SAH patients was an independent predictor of developing hyponatremia.



A retrospective review on the health records of 106 patients admitted to the University of Alberta Hospital Neurosciences ICU, Edmonton AB, Canada, with SAH from June 2013 to December 2015 was conducted. Serum sodium changes in patients receiving vasoactive drugs were compared. In addition, independent predictors for hyponatremia (Na < 135 mmol/L) were determined using a multivariate logistic regression model.



Patients treated with vasopressin in addition to other vasoactive drugs had significantly higher sodium changes compared to those treated with other vasoactive drugs (-4.7 ± 6 vs -0.1 ± 2.4 mmol/L, respectively, p value 0.001). Hyponatremia occurred in 14 patients (70 %) treated with vasopressin, 10 patients (44 %) treated with vasoactive drugs other than vasopressin (p value 0.081), and 24 patients (38 %) who did not receive any vasoactive drug (p value 0.013). In multivariate logistic regression analysis, when adjusting for disease severity, age, sex, aneurysm location, and treatment, vasopressin was associated with hyponatremia (OR 3.58, 95 % CI, 1.02-12.5, p value 0.046).



The results of the present study suggest that hyponatremia may be more common in SAH patients treated with exogenous vasopressin compared to those who did not receive it. Serum sodium should be monitored closely when vasopressin is being used in the SAH population. Further studies are needed to confirm the effect of exogenous vasopressin on serum sodium levels in SAH populations.
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada.
Nancy
N
Marr
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada.
Jessica
J
Yu
Division of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Demetrios J
DJ
Kutsogiannis
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada. smahmoud@ualberta.ca.
Sherif Hanafy
SH
Mahmoud
D000328:Adult; D005260:Female; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy*; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000494:pharmacology*; D014667:Vasopressins / Q000008:administration & dosage / Q000494:pharmacology*
D014662:Vasoconstrictor Agents; D014667:Vasopressins
Hypertonic saline; Hyponatremia; Subarachnoid hemorrhage; Vasopressin; Vasopressors
Neurocrit Care. 2007;6(1):3-10
17356185
J Biomed Inform. 2009 Apr;42(2):377-81
18929686
Stroke. 2012 Jun;43(6):1711-37
22556195
N Engl J Med. 2008 Feb 28;358(9):877-87
18305265
J Neurol Neurosurg Psychiatry. 1981 Mar;44(3):216-9
7229644
Neurol Res. 2000 Mar;22(2):151-5
10763501
Neurocrit Care. 2011 Sep;15(2):211-40
21773873
J Clin Endocrinol Metab. 2014 Jan;99(1):291-8
24248182
Kidney Int. 2004 Jan;65(1):54-62
14675036
Crit Care Med. 2003 Jun;31(6):1752-8
12794416
World Neurosurg. 2016 Jan;85:305-14
26361321
J Biomed Inform. 2013 Apr;46(2):259-65
23149159
N Engl J Med. 2006 Jan 26;354(4):387-96
16436770
Ann Neurol. 1985 Feb;17(2):137-40
3977297
J Intensive Care Med. 2015 Jul;30(5):253-8
24106070
J Neurosci Rural Pract. 2013 Jan;4(1):24-8
23546343
Ann Neurol. 1985 Aug;18(2):211-6
4037761
Brain Res. 2016 May 15;1639:108-19
26940841
Ann Neurol. 1992 May;31(5):543-50
1534478
Ann Pharmacother. 2004 Jul-Aug;38(7-8):1117-22
15178740